LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Novel bis-amide-based bis-thiazoles as anti-colorectal cancer agents through Bcl-2 inhibition: Synthesis, In Vitro, and In Vivo studies.

Photo by nci from unsplash

BACKGROUND Some heterocycles having bisamide linkage are receiving much interest due to their remarkable biological potencies and their naturally occurring. Some bisamides and thiazole derivatives were found to inhibit the… Click to show full abstract

BACKGROUND Some heterocycles having bisamide linkage are receiving much interest due to their remarkable biological potencies and their naturally occurring. Some bisamides and thiazole derivatives were found to inhibit the protein levels of Bcl-2 significantly. This promoted us to synthesize new bis(heterocyclic) derivatives having bisamide function to explore their anti-cancer activities. METHOD Novel bis-amide-based bis-thiazoles and thiadiazoles were synthesized by reaction of a new bis-thiosemicarbazone with variety of hydrazonoyl chlorides, -chloroacetylacetone and haloacetic acid derivatives. Most of the synthesized derivatives were tested for colorectal (HCT-116), and breast (MCF-7) cell lines using the MTT assay, with apoptotic investigation through flow cytometric and RT-PCR analyses. RESULTS Some derivatives were found to be highly cytotoxic against HCT-116 cells with IC50 range of (10.44-13.76 µM) compared to 5-fluorouracil (5-FU) (IC50 = 11.78 µM). One product significantly stimulated apoptotic colorectal cancer cell death by 27.24-fold (50.13% compared to control 1.84%) by arresting the cell cycle at the G2/M phase. The obtained results revealed that compound 7f was more cytotoxic against HCT-116 cells than 5-FU. Compound 7f remarkably enhanced apoptotic colorectal cancer cell death and upregulated the propapoptotic genes (P53, BAX and Capases-3,-8,-9) and downregulated the anti-apoptotic gene, B-cell lymphoma 2 (Bcl-2). In Vivo study, exhibited that 7f-treatment caused tumor inhibition ratio (TIR%) with 50.45% compared to 54.86% in the 5-FU treatment, with a significant reduction in tumor mass and volume. The anti-tumor activity of compound 7f was accompanied by ameliorated hematological and biochemical analyses, histopathological improvenmnet in treated liver tissues, and the immunohistochemical staining revealed Bcl-2 inhibition in agreement with the in vitro results. CONCLUSION Compound 7f is an interesting candidate for further development as a chemotherapeutic anti-cancer agent.

Keywords: cell; inhibition; bis; colorectal cancer; novel bis; cancer

Journal Title: Anti-cancer agents in medicinal chemistry
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.